€157.2m market cap
€1.89 last close
Transgene is a French company developing immunotherapy agents for cancer and infectious diseases. Oncolytic virus Pexa-Vec (Phase III for HCC) and cancer vaccine TG4010 (Phase II for NSCLC) are the lead clinical candidates.
Investment summary
Transgene is developing viral vector-based immunotherapies for combination therapies in oncology and infectious diseases. The company is running multiple clinical trials, notably a Phase II trial combining TG4010 with Opdivo and chemotherapy in first-line NSCLC. Transgene and partner SillaJen have announced the termination of the global 600-patient Phase III study (PHOCUS) for Pexa-Vec+sorafenib in advanced liver cancer. Next-generation platforms Invir.IO and myvac continue to progress, with new myvac asset TG4040 expected to enter the clinic in H219. Transgene has announced a new collaboration and licensing agreement with AZN for its Invir.IO platform and received €10m on signing. Gross cash and short-term investments at 30 September 2019 were €53.9m.
Y/E Dec |
Revenue (€m) |
EBITDA (€m) |
PBT (€m) |
EPS (c) |
P/E (x) |
P/CF (x) |
|---|---|---|---|---|---|---|
| 2017A | 8.1 | (26.4) | (35.0) | (53.1) | N/A | N/A |
| 2018A | 42.9 | 9.1 | (36.8) | (44.7) | N/A | N/A |
| 2019E | 16.9 | (12.0) | (15.9) | (20.9) | N/A | N/A |
| 2020E | 4.9 | (24.3) | (27.6) | (33.1) | N/A | N/A |
Industry outlook
Immunotherapies are one of the most promising classes of products for cancer. Increased attention is now being paid to the use of combination therapy approaches to improve cancer response rates.
Last updated on 04/12/2019
Sector |
|---|
| Healthcare |
Share price graph
Balance sheet |
|
|---|---|
| Forecast net debt (€m) | 13.7 |
| Forecast gearing ratio (%) | 19 |
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| Philippe Archinard | Chairman & CEO |
| Lucie Larguier | Director of IR |
You may also be interested in…
- 4SC
- Acacia Pharma
- Acarix
- ADL Bionatur Solutions
- Adocia
- ASIT biotech
- Basilea Pharmaceutica
- BioPorto Diagnostics
- Bonesupport
- Brighter
- Cantargia
- Carmat
- Celyad
- Deinove
- Formycon
- Herantis Pharma
- Hybrigenics
- Immunicum
- Immunovia
- Kiadis Pharma
- Laboratorios Farmacéuticos ROVI
- MagForce
- Medigene
- MOLOGEN
- Nanobiotix
- NeuroVive Pharmaceutical
- Newron Pharmaceuticals
- Nuevolution
- Oncology Venture
- Onxeo
- Orexo
- Oryzon Genomics
- OSE Immunotherapeutics
- Paion
- Photocure
- Pixium Vision
- Probiodrug
- Quantum Genomics
- RhoVac
- Ryvu Therapeutics
- Targovax
- TxCell
- Xbrane Biopharma